Recent Phase 1 and Phase 2 trials demonstrate the safety and immunogenicity of a 24-valent pneumococcal conjugate vaccine in healthy Chinese adults. These findings contribute to the ongoing research in vaccine development for pneumococcal diseases.
safety and immunogenicity of the 24 valent pneumococcal conjugate vaccine in healthy chinese adults two single center randomized double blind phase 1 and phase 2 trials
Original title: “Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials.”